Saturday, April 6, 2013

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review

World J Hepatol. 2013 March 27; 5(3): 120-126.
Published online 2013 March 27. doi: 10.4254/wjh.v5.i3.120.

Copyright©2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Simona Bota, Ioan Sporea, Roxana Şirli, Alina Popescu, Adriana Maria Neghină, Mirela Dănilă and Mihnea Străin.
Simona Bota, Ioan Sporea, Roxana Şirli, Alina Popescu, Mirela Dănilă, Mihnea Străin, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, 300736 Timişoara, Romania
Adriana Maria Neghină, Department of Biochemistry and Pharmacology, University of Medicine and Pharmacy, 300736 Timişoara, Romania
Author contributions: Bota S, Sporea I and Şirli R designed the manuscript; Bota S wrote the manuscript; Bota S, Şirli R, Popescu A and Neghină AM acquired the data; Bota S and Neghină AM performed the statistical analysis; Bota S, Sporea I, Şirli R, Popescu A, Dănilă M and Strain M interpreted the data; Sporea I, Şirli R, Popescu A, Neghina AM, Dănilă M and Străin M revised the manuscript draft; Bota S, Sporea I, Şirli R, Popescu A, Neghină AM, Dănilă M and Străin M approved the final version of the article.
Correspondence to: Simona Bota, MD, Department of Gastroenterology, University of Medicine and Pharmacy, 300736 Timişoara, Romania.
bota_simona1982@yahoo.com
Telephone: +40-721-656147 Fax: +40-256-488003
Received June 18, 2012; Revised November 26, 2012; Accepted January 17, 2013;


Abstract
AIM: To identify severe adverse events (SAEs) leading to treatment discontinuation that occur during antiviral therapy in hepatitis C virus (HCV)-infected cirrhotic patients.
METHODS: We identified all the articles published prior to December 2011 in the PubMed, Medline, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases that presented these data in cirrhotic patients. These studies evaluated the rate of SAEs leading to discontinuation of standard care treatment: Pegylated interferon (PegIFN) alpha 2a (135-180 μg/wk) or PegIFN alpha 2b (1 or 1.5 μg/kg per week) and ribavirin (800-1200 mg/d). Patients with genotype 1 + 4 underwent treatment for 48 wk, whereas those with genotypes 2 + 3 were treated for 24 wk.
 
RESULTS: We included 17 papers in this review, comprising of 1133 patients. Treatment was discontinued due to SAEs in 14.5% of the patients. The most common SAEs were: severe thrombocytopenia and/or neutropenia (23.2%), psychiatric disorders (15.5%), decompensation of liver cirrhosis (12.1%) and severe anemia (11.2%). The proportion of patients who needed to discontinue their therapy due to SAEs was significantly higher in patients with Child-Pugh class B and C vs those with Child-Pugh class A: 22% vs 11.4% (P = 0.003). A similar discontinuation rate was found in cirrhotic patients treated with PegIFN alpha 2a and those treated with PegIFN alpha 2b, in combination with ribavirin: 14.2% vs 13.7% (P = 0.96). The overall sustained virological response rate in cirrhotic patients was 37% (95%CI: 33.5-43.1) but was significantly lower in patients with genotype 1 + 4 than in those with genotype 2 + 3: 20.5% (95%CI: 17.9-24.8) vs 56.5% (95%CI: 51.5-63.2), (P < 0.0001).
 
CONCLUSION: Fourteen point five percent of HCV cirrhotic patients treated with PegIFN and ribavirin needed early discontinuation of therapy due to SAEs, the most common cause being hematological disorders.
 
Keywords: Liver cirrhosis, Hepatitis C virus, Adverse events, Sustained virological response
 
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a worldwide public health concern, affecting approximately 170 million people[1]. This condition is responsible for 25%-30% of global cases of cirrhosis and is the most common cause for liver transplantation[2]. Cirrhotic patients infected with HCV develop hepatic decompensation at a rate of 30% over 10 years and hepatocellular carcinoma at annual rates ranging from 3% to 8%[3,4].
 
In the last 10 years, pegylated interferon (PegIFN) and ribavirin became the standard of care (SOC) treatment in chronic HCV infection. The sustained virological response (SVR) rates range from 42% to 46% in patients with genotype 1 or 4 infection and from 76% to 82% in patients with genotype 2 or 3 infection[5-7]. In patients with liver cirrhosis, the SVR rate is even lower, at approximately 20% in genotype 1 or 4 infection and 55% in patients with genotype 2 or 3 infection[8]. Also, cirrhotic patients have a reduced tolerance to therapy[9,10] but the risk of further complications is smaller in patients who achieve SVR[11].
 
This systematic review aims to identify and analyze the severe adverse events (SAE) that lead to treatment discontinuation during treatment with PegIFN and ribavirin in cirrhotic patients infected with HCV.
 
MATERIALS AND METHODS
Eligibility criteria
 
This review included all the studies published in English prior to December 2011 that evaluated SAEs in cirrhotic patients infected with HCV and treated with SOC therapy: PegIFN alpha 2a (dosage: 135-180 μg/wk) or PegIFN alpha 2b (dosage: 1 or 1.5 μg/kg per week) and ribavirin (dosage range: 800-1200 mg/d). Patients with genotype 1 + 4 underwent treatment for 48 wk, whereas those with genotypes 2 + 3 were treated for 24 wk. The diagnosis of cirrhosis was made either by liver biopsy or by clinical, ultrasonographic, endoscopic or laparoscopic signs of cirrhosis. Studies that included liver-transplanted patients or cases co-infected with hepatitis B virus or human immunodeficiency virus were excluded from the analysis.
 
Outcomes
The pre-specified primary outcome was the rate of SAEs (leading to treatment discontinuation) that occurred during treatment with PegIFN and ribavirin in cirrhotic patients infected with HCV.
The secondary outcomes were: description of SAEs; the possible relationships between SAE rates in cirrhotic patients and the following factors: decompensation of the disease (class Child-Pugh B or C), type of PegIFN (alpha 2a and alpha 2b) used in SOC therapy and HCV genotype; the proportion of patients in whom the medication dosage was reduced; and the SVR rate in cirrhotic patients, according to HCV genotype.
SVR was defined as undetectable HCV RNA in serum by real-time polymerase chain reaction 6 mo after discontinuation of therapy.
 
Data sources and searches
Relevant studies published prior to December 2011 were searched in PubMed, Medline, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases using the following keywords: liver cirrhosis, chronic hepatitis C, HCV, adverse events, sustained virological response, SVR.
Study selection and data collection
 
Two authors independently screened titles and abstracts for potential eligibility and the full texts for final eligibility. The following data were extracted: country of origin, year of publication, number of patients, age and weight of the patients, HCV genotype, the Child-Pugh class, the baseline treatment history (naive or previously treated), the treatment administered, the rate and description of SAEs that lead to treatment discontinuation, the proportion of patients in whom the doses of PegIFN and/or ribavirin were reduced, and the SVR rate according to HCV genotype.
Statistical analysis
 
Statistical analysis were carried out with the software package SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL). Descriptive statistics (percentage, 95%CI) were calculated for each variable as appropriate. Standard binomial tests for differences in proportions were used to compare patient subgroups (“n” designates the total number of patients included in a particular subgroup). A P value of less than 0.05 was regarded as statistically significant.
 
RESULTS
Of 8793 titles identified during the initial search, 8764 were excluded based on one of the following reasons: data published only in abstract, duplicated titles, data on cirrhotic patients not presented, the treatment regimen did not include PegIFN in combination with ribavirin or the same author had several similar articles, but with a different number of patients (we selected the article with the higher number of patients if we did not receive the information regarding the number of patients included in two or more studies from the author). Twelve articles which presented data on cirrhotic patients were excluded for the following reasons: the dosage or treatment duration with PegIFN and ribavirin were not standard; liver-transplanted patients were included; and the study presented the follow-up of patients after SOC therapy, but not the SAE leading to the therapy discontinuation. Finally, seventeen papers with 1133 patients with HCV liver cirrhosis were retrieved for analysis[12-28] (Figure 1). The main characteristics of the studies included in this systematic review are presented in Table 1.
 
Table 1
Characteristics of the studies included in the systematic analysis
 
Ref.Study designNo. of patientsAge (yr)WeightHCV genotypeBaseline treatment historyChild-Pugh classTreatment
Syed et al[12]Retrospective cohort study10452 ± 7.682 ± 15 kg (mean weight)1, 2, 3Naive and previously treatedAPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1-1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Butt et al[13]Prospective cohort study6646.2 ± 10.122.3 ± 3.1 kg/m² (mean BMI)3Naive and previously treatedA, BPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Giannini et al[14]Retrospective cohort study8556 ± 9Not specified1, 2, 3, 4Naive and previously treatedA, BPegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/ d)
Helbling et al[15]Randomized controlled trial (standard doses vs low doses)6447 (median age)74 kg (median weight)1, 2, 3, 4NaiveAPegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/ d)
Iacobellis et al[16]Prospective cohort study94Not specifiedNot specified1, 2, 3, 4NaiveBPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Roffi et al[17]Randomized controlled trial (pegylated interferon vs IFN standard)5756 (median age)75 kg (median weight)1, 2, 3NaiveAPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800-1200 mg/d)
Sood et al[18]Retrospective cohort study2848.3 ± 773.9 ± 11.2 kg (mean weight)3 (25/28 patients) and not specified for the other patientsNaiveA, BPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Tekin et al[19]Cohort study2054.2 ± 5.9Not specified1Not specifiedA, BPegylated interferon alpha 2a (135 μg/wk)
Ribavirin (1000-1200 mg/d)
Moreno Planas et al[20]Cohort study1252 ± 8Not specified1, 3Naive and previously treatedA, BPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (10.6 mg/kg per day)
Di Marco et al[21]Randomized controlled trial (pegylated interferon alpha 2B + ribavirin vs pegylated interferon alpha 2b)5257 ± 6.671 ± 10.1 kg (mean weight)1, 2, 3, 4Naive and previously treatedA, BPegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800 mg/d)
Höroldt et al[22]Retrospective cohort study61Not specifiedNot specified1, 2, 3NaiveA, BPegylated interferon alpha 2a or alpha 2b + ribavirin
Bruno et al[23]Randomized study106Not specifiedNot specified1, 2, 3, 4NaiveAPegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Floreani et al[24]Prospective cohort study8755.7 ± 9.125.3 ± 3.1 kg/m² (mean BMI)1, 2, 3NaiveAPegylated interferon alpha 2b (80-100 μg/wk)
Ribavirin (1000-1200 mg/d)
Annicchiarico et al[25]Prospective cohort study1551.5Not specified1, 2, 3Naive and previously treatedB, CPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Aghemo et al[26]Prospective cohort study10657 ± 9.372.5 ± 11.8 kg (mean weight)1, 2, 3, 4NaiveAPegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (≥ 10.6 mg/kg per day)
Kim et al[27]Cohort study8656.4 ± 9.6Not specified1 and non-1Not specifiedAPegylated interferon alpha 2b (1.5 μg/kg per week)
or Pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Reiberger et al[28]Prospective cohort study9051 ± 826.6 ± 5 kg/m² (mean BMI)1, 2, 3, 4Not specifiedAPegylated interferon alpha 2b (1.5 μg/kg per week)
or pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
HCV: Hepatitis C virus; BMI: Body mass index; IFN: Interferon.
 
 
 
Figure 1
Flowchart of the selection of the studies. SOC: Standard of care; SAE: Severe adverse event.
 
 
Table 2
Description of severe adverse event leading to premature discontinuation of antiviral treatment in hepatitis C virus cirrhotic patients (%)
 
Name of severe adverse eventNo. of patient discontinuities
Severe thrombocytopenia and/or neutropenia27 (23.2)
Psychiatric disorders (depression, psychosis, confusion, lethargy)18 (15.5)
Decompensation of liver cirrhosis (ascites with or without spontaneous bacterial peritonitis; jaundice; hepatic encephalopathy)14 (12.1)
Severe anemia13 (11.2)
Occurrence of malignancies6 (5.1) - 4 cases of hepatocellular carcinoma, 1 case of tongue carcinoma and 1 case of Non-Hodgkin’s lymphoma recurrence
Allergic reactions to medication5 (4.3)
Severe infections5 (4.3)
Severe fatigue5 (4.3) - in 2 cases accompanied also by “flu-like” syndrome
Neurological disorders (stroke, polyneuropathy, hemiparesthesia)5 (4.3)
Heart disease (heart failure or acute coronary syndrome)3 (2.5)
Endocrinology disorders3 (2.5)
Diabetes decompensation2 (1.7)
Persistent fever2 (1.7)
Severe denutrition2 (1.7)
Aminotransferases flare1 (0.8)
Severe decrease of vision1 (0.8)
Upper gastrointestinal bleeding1 (0.8) - the cause of bleeding was not specified
Acute pancreatitis1 (0.8)
Severe flare of psoriasis1 (0.8)

World J Hepatol. 2013 March 27; 5(3): 120–126.
Published online 2013 March 27. doi: 10.4254/wjh.v5.i3.120.

Friday, April 5, 2013

VX-135/daclatasvir: Vertex signs agreement with Bristol-Myers for all-oral midstage studies for hepatitis C treatments


Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C

-Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir-

-Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-

-Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013-

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYSE: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naïve people with genotype 1 HCV infection planned for the second quarter of 2013. Vertex plans to begin a subsequent study in treatment-naïve people infected with genotype 1, 2 or 3 HCV, including those with cirrhosis, in the second half of 2013, pending data from the initial study.

"With more than 170 million people infected worldwide, there is a critical need for new hepatitis C medicines that can offer people simpler and more tolerable treatment regimens that provide high cure rates," said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer at Vertex. "These studies with daclatasvir will provide the first opportunity to evaluate VX-135 as part of all-oral regimens in people with multiple hepatitis C genotypes and in people with cirrhosis."

Clinical Development Plans for VX-135 with Daclatasvir

Under the terms of the agreement, Vertex will conduct two Phase 2 studies of VX-135 in combination with daclatasvir. The first study will enroll approximately 20 non-cirrhotic, treatment-naïve people with chronic genotype 1 HCV infection and is expected to begin in the second quarter of 2013. In the second half of 2013, Vertex plans to conduct a subsequent study in approximately 250 treatment-naïve people with chronic genotype 1, 2 or 3 HCV infection, including those with cirrhosis. Each of these studies is expected to evaluate safety, tolerability, pharmacokinetics and viral cure rates (SVR4 and SVR12) of multiple all-oral regimens of VX-135 and daclatasvir dosed once daily, pending regulatory discussions. Vertex will also conduct co-formulation activities to evaluate the potential for development of a once-daily fixed-dose combination regimen. Further clinical development activities beyond the Phase 2 studies are not covered as part of this agreement.

About VX-135

VX-135 is a uridine nucleotide analogue pro-drug designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. In people with genotype 1, treatment with a 200mg once-daily dose of VX-135 in a 7-day viral kinetic study was well-tolerated, with no discontinuations due to adverse events, and resulted in a 4.54 log10 median reduction from baseline in HCV RNA. Data from a 7-day viral kinetic study of VX-135 in people with genotypes 2, 3 and 4 were consistent with data observed in people with genotype 1 and have been submitted for presentation at a future medical meeting.

Vertex gained worldwide rights to ALS-2200, known as VX-135 in Phase 2 studies, through an exclusive licensing agreement signed with Alios BioPharma, Inc. in June 2011. The agreement also includes a research program that focuses on the discovery of additional nucleotide analogues that act on hepatitis C polymerase. Vertex has the option to select additional compounds for development emerging from the research program.

About Daclatasvir

Daclatasvir is an NS5A replication complex inhibitor that is being extensively studied as a key component of potential DAA-based hepatitis C treatment regimens. Studied in more than 4,100 patients to date, daclatasvir is in Phase 3 development.

Daclatasvir is part of a portfolio of investigational compounds with different mechanisms of action that Bristol-Myers Squibb is developing for the treatment of hepatitis C. These compounds are being studied as part of multiple novel treatment regimens with the goal of increasing SVR rates across diverse patient types and geographies.

About Hepatitis C

Hepatitis C is a serious liver infection caused by the hepatitis C virus, which is spread through direct contact with the blood of infected people and ultimately affects the liver.1 Chronic hepatitis C can lead to serious and life-threatening liver problems, including liver damage, cirrhosis, liver failure or liver cancer.1 Though many people with hepatitis C may not experience symptoms, others may have symptoms such as fatigue, fever, jaundice and abdominal pain.1 Unlike HIV and hepatitis B virus, chronic hepatitis C can be cured.2 If treatment is not successful and a person does not achieve a viral cure, they remain at an increased risk for progressive liver disease.3,4

More than 170 million people worldwide are chronically infected with hepatitis C.5 In the United States, up to 5 million people have chronic hepatitis C and 75 percent of them are unaware of their infection.6,7 Hepatitis C is four times more prevalent in the United States compared to HIV.7 The majority of people with hepatitis C in the United States were born between 1945 and 1965, accounting for three fourths of people with the infection.8 Hepatitis C is the leading cause of liver transplantations in the United States and is reported to contribute to 15,000 deaths annually.9,10 By 2029, total annual medical costs in the United States for people with hepatitis C are expected to more than double, from $30 billion in 2009 to approximately $85 billion.11

About Vertex

Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases.

Founded more than 20 years ago in Cambridge, Mass., we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada. Today, Vertex has more than 2,000 employees around the world, and for three years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.

Vertex Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Kauffman's statements in the second paragraph of the press release and statements regarding Vertex's expectations with respect to the timing and structure of studies evaluating the combination of VX-135 and daclatasvir. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that the initiation of planned studies may be delayed or prevented, that the outcomes of Vertex's planned clinical studies may not be favorable and other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

References:

1 Centers for Disease Control and Prevention. Hepatitis C Fact Sheet: CDC Viral Hepatitis. Available at: http://www.cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf Updated June 2010. Accessed September 21, 2012.

2 Pearlman BL and Traub N. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clin Infect Dis. 2011 Apr;52(7):889-900.

3 Morgan TR, Ghany MG, Kim HY, Snow KK, Lindsay K, Lok AS. Outcome of sustained virological responders and non-responders in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. Hepatology. 2008;50(Suppl 4):357A (Abstract 115).

4 Veldt BJ, Heathcote J, Wedmeyer H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Annals of Internal Medicine. 2007; 147: 677-684.

5 Ghany MG, Strader DB, Thomas DL, Seeff, LB. Diagnosis, management and treatment of hepatitis C; An update. Hepatology. 2009;49 (4):1-40.

6 Chak, E, et. al. Hepatitis C Virus Infection In USA: An Estimate of True Prevalence. Liver Intl. 2011;1096 -1098.

7 Institute of Medicine of the National Academies. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Colvin HM and Mitchell AE, ed. Available at: http://www.iom.edu/Reports/2010/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx Updated January 11, 2010. Accessed September 21, 2012.

8 Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945—1965. Morbidity and Mortality Weekly Report. August 17, 2012; 61(RR04);1-18.

9 Volk MI, Tocco R, Saini S, Lok, ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.

10 Ly KN, et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med. 2012;156:271-278.

11 Pyenson B, Fitch K, and Iwasaki K. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease. Milliman, Inc. May 2009. Available at: http://www.vrtx.com/assets/pdfs/MillimanReport.pdf

VRTX — GEN


Vertex Pharmaceuticals Incorporated
Media:
Zach Barber, 617-341-6470
mediainfo@vrtx.com
or
Investors:
Michael Partridge, 617-341-6108
or
Kelly Lewis, 617-961-7530

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media 

Vertex Signs Deal With Bristol-Myers for Hepatitis C Treatment Studies

Vertex Pharmaceuticals Inc. (VRTX) entered a nonexclusive agreement with Bristol-Myers Squibb Co. (BMY) to conduct midstage studies for hepatitis C treatments, its latest collaboration as part of its push to develop treatments for the liver disease.

The Phase 2 studies are for once-daily all-oral treatment regimens containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir.

As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in treatment-naive people with genotype 1 hepatitis C virus, planned for the second quarter.

Vertex plans to begin a subsequent study in treatment-naive people infected with genotype 1, 2 or 3 hepatitis C virus, including those with cirrhosis, in the second half, pending data from the initial study.

"With more than 170 million people infected worldwide, there is a critical need for new hepatitis C medicines that can offer people simpler and more tolerable treatment regimens that provide high cure rates," Vertex Chief Medical Officer Robert Kauffman said. "These studies with daclatasvir will provide the first opportunity to evaluate VX-135 as part of all-oral regimens in people with multiple hepatitis C genotypes and in people with cirrhosis."

Treatments for hepatitis C are considered lucrative because the disease is prevalent in large sections of the global population. The virus, which can be transmitted sexually or through use of shared needles and at tattoo parlors, affects some 170 million people world-wide.

Both Vertex and Bristol-Myers have grappled with setbacks in their push to develop treatments for hepatitis C. In August, Bristol-Myers said it had suspended its study of a drug intended to treat hepatitis C after a patient suffered heart failure, which the company called a "serious safety issue."

Meanwhile in December, the Food and Drug Administration placed a new label on Vertex's hepatitis C drug Incivek, warning patients that the drug has caused fatal skin rashes in some patients.

The latest collaboration comes after Vertex in November teamed up with two rivals to study potential new treatments for hepatitis C. In separate partnerships, Vertex said it would begin mid-stage trials in 2013 to study its investigational drug VX-135 in combination with treatments being developed by GlaxoSmithKline PLC (GSK) and Johnson & Johnson's (JNJ) Janssen Pharmaceuticals unit.

Shares of Vertex closed Thursday at $52.95, while those of Bristol-Myers closed at $40.78. Both stocks were inactive premarket.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Copyright © 2013 Dow Jones Newswires

Read more

Hepatitis C Virus Vaccines in the Era of New Direct-acting Antivirals

 
Hepatitis C Virus Vaccines in the Era of New Direct-acting Antivirals
Chao Shi, Alexander Ploss
Disclosures
Expert Rev Gastroenterol Hepatol. 2013;7(2):171-185.

Hepatitis C virus (HCV) infection is a major global health problem as it has a high propensity for establishing chronicity. Chronic HCV carriers are at risk of developing severe liver disease including fibrosis, cirrhosis and liver cancer. While treatment has considerably improved over the years, therapy is still only partially effective, and is plagued by side effects, which contribute to treatment failure and is expensive to manage. The drug development pipeline contains several compounds that hold promise to achieve the goal of a short and more tolerable therapy, and are also likely to improve treatment response rates. It remains to be seen, however, how potent antiviral drug cocktails will affect the hepatitis C burden worldwide. In resource-poor environments, considerable costs, inadequate infrastructure for medical supervision and distribution may diminish the impact of future therapies. Consequently, development of novel therapeutic and prophylactic strategies is imperative to contain HCV infection globally.

Read more @ Medscape

  • Prospects in HCV Treatment
  • Unmet Demands
  • HCV Vaccines
  • Current HCV Vaccine Research
  • Recent Progress in the Model Systems for Vaccine Studies
  • Adapting HCV to Infect Nonpermissive Species
  • Engineering the Hosts to Accommodate HCV
  • Expert Commentary
  • Five-year View

  • Free registration required